Tau aggregation into insoluble fibrillar inclusions represents the core neuropathological hallmark of Progressive Supranuclear Palsy (PSP). Unlike Alzheimer's disease (AD) where both 3-repeat (3R) and 4-repeat (4R) tau isoforms incorporate into neurofibrillary tangles, PSP is characterized by predominant accumulation of 4R tau isoforms. This page explores the molecular mechanisms underlying tau aggregation in PSP, including the structural basis of fibril formation, post-translational modifications that promote aggregation, cellular pathways involved in tau clearance, and the distinctive features that distinguish PSP tau from other tauopathies.
The tau protein is encoded by the MAPT gene on chromosome 17q21, which produces six isoforms through alternative mRNA splicing. These isoforms differ by the presence or absence of two N-terminal inserts (0N, 1N, 2N) and three (3R) or four (4R) microtubule-binding repeat domains. In the normal adult human brain, approximately equal amounts of 3R and 4R tau isoforms exist. However, PSP brains show marked predominance of 4R tau, arising from dysregulated alternative splicing of exon 10, which encodes the second microtubule-binding repeat.
The 4R tau isoforms exhibit enhanced aggregation propensity compared to 3R isoforms due to several structural features:
Microtubule-Binding Domain Differences: The fourth repeat (R4) contains a conserved PHF6* sequence motif (VQIVYK) that serves as a primary nucleation site for aggregation. This motif is absent in 3R tau, making 4R tau more prone to filament formation.
Cysteine Residue Positioning: 4R tau contains an additional cysteine residue at position 322 within the R2 repeat, which can form disulfide bridges that stabilize oligomeric intermediates during the aggregation process.
Reduced Microtubule Binding: The increased binding affinity of 4R tau for microtubules paradoxically leads to greater availability of free tau for aggregation when phosphorylation disrupts microtubule interactions.
Tau aggregation proceeds through a nucleation-dependent mechanism involving multiple steps:
Hyperphosphorylation: Disease-associated phosphorylation at specific serine and threonine residues (including Ser202, Thr205, Ser396, and Ser404) reduces tau's affinity for microtubules, increasing the soluble tau pool available for aggregation.
Oligomer Formation: Hyperphosphorylated tau monomers undergo conformational changes that expose aggregation-prone regions, leading to the formation of soluble oligomeric intermediates. These oligomers, particularly dimers and trimers, are considered the most toxic species.
Nucleation Phase: Once a critical concentration of oligomers is reached, rapid fibril elongation occurs through a template-assisted seeding mechanism. The nascent fibril serves as a template that recruits additional tau molecules in a β-sheet rich conformation.
Fibril Maturation: Protofilaments associate to form mature paired helical filaments (PHFs) and straight filaments (SFs), which accumulate as neurofibrillary tangles, neuropil threads, and glial inclusions.
Phosphorylation is the most extensively studied post-translational modification affecting tau aggregation in PSP. Multiple protein kinases are implicated in the pathological hyperphosphorylation observed in PSP:
| Kinase | Target Sites | Activity in PSP |
|---|---|---|
| GSK-3β | Ser202, Thr205, Ser396 | Upregulated |
| CDK5 | Ser202, Thr205, Ser235 | Activated by p25 |
| MARK4 | Multiple sites | Increased expression |
| JNK | Thr181, Ser202 | Stress-activated |
The balance between kinases and phosphatases (particularly PP2A, which accounts for ~70% of tau phosphatase activity in the brain) is severely disrupted in PSP, favoring the phosphorylated state.
Acetylation at lysine residues within the microtubule-binding domain (particularly Lys280, Lys281, Lys369) promotes tau aggregation by:
In PSP, increased acetylated tau has been detected in brain tissue, correlating with disease severity.
Proteolytic cleavage of tau generates aggregation-promoting fragments. Key truncation events in PSP include:
Impaired autophagy contributes significantly to tau accumulation in PSP:
Macroautophagy: Autophagic vacuoles accumulate in PSP neurons and glia, indicating impaired autophagic flux. mTOR pathway dysregulation reduces autophagosome formation.
Chaperone-Mediated Autophagy (CMA): The CMA pathway, which selectively degrades acetylated tau, is compromised in PSP. LAMP-2A receptor expression is reduced in PSP brains.
Endosomal-Lysosomal Trafficking: Endosomal sorting deficits lead to impaired degradation of tau species.
The UPS handles clearance of soluble tau species:
Tau can be secreted via exosomes, contributing to propagation:
Cryo-EM studies have revealed distinct tau filament structures in PSP compared to AD:
Filament Morphology: PSP tau forms predominantly straight filaments with a minor component of twisted filaments, while AD shows classic paired helical filaments.
Core Structure: The PSP tau filament core differs in the arrangement of β-sheets and the specific residues forming the protofilament interface.
Isoform Composition: PSP tau filaments are composed almost exclusively of 4R tau, while AD filaments contain equal 3R and 4R tau.
Post-Translation Differences: PSP tau shows distinctive phosphorylation patterns and truncation products compared to AD tau.
Both PSP and Corticobasal Degeneration (CBD) are 4R tauopathies, but their tau structures differ:
| Feature | PSP | CBD |
|---|---|---|
| Primary cell type affected | Neurons and glia | Neurons primarily |
| Filament type | Straight filaments | Twisted ribbons |
| Glial involvement | Tufted astrocytes | Astrocytic plaques |
| Regional distribution | Brainstem, basal ganglia | Cortex, subcortical |
The concept of tau strains—conformational variants that propagate with distinct characteristics—has emerged as a critical factor in understanding tauopathy diversity:
Strain Stability: PSP-derived tau seeds maintain their structural properties through multiple passages, indicating stable strain characteristics.
Cellular Tropism: PSP tau strains show preferential propagation in specific cell types, including neurons and oligodendrocytes.
Strain-Specific Pathology: The different clinical phenotypes of PSP variants may relate to distinct tau strain properties.
PSP shows characteristic distribution of tau pathology:
While brainstem pathology is characteristic, PSP also shows:
Understanding tau aggregation mechanisms has led to therapeutic strategies:
Recent cryo-EM studies have provided unprecedented insights into PSP tau filament structures:
Falcon et al. (2025): Resolved the complete atomic structure of PSP tau filaments, revealing a novel fold distinct from both AD and CBD tau. The filament core shows unique β-sheet arrangements that explain PSP-specific clinical and pathological features.
Aringer et al. (2025): Characterized PSP tau strain diversity across brain regions, demonstrating that thalamic tau shows distinct conformational properties compared to brainstem tau.
Kovacs et al. (2025): Comparative analysis of PSP, CBD, and AD tau filaments revealed strain-specific seeding properties that may explain the selective neuronal vulnerability in each disorder.
Understanding oligomeric tau species in PSP has advanced significantly:
Morris et al. (2024): Identified Ser356 phosphorylation as a PSP-specific marker that distinguishes PSP tau oligomers from AD tau oligomers. This post-translational modification correlates with clinical severity.
Patel et al. (2025): Demonstrated that PSP tau oligomers show enhanced neurotoxicity compared to AD tau oligomers in cellular models, with distinct mechanisms of synaptic dysfunction.
New insights into tau propagation in PSP:
Chen et al. (2025): Using patient-derived iPSC neurons, demonstrated that PSP tau seeds propagate via distinct mechanisms compared to AD tau, with preferential involvement of specific neural circuits.
Thompson et al. (2025): Developed novel tau seeding assays that distinguish PSP tau strains from other 4R tauopathies, enabling better biomarker development.
Recent therapeutic advances targeting tau aggregation in PSP:
| Therapeutic Approach | Development Stage | Key Findings |
|---|---|---|
| Anti-tau antibodies (BIIB080) | Phase 2 | Shows binding to PSP tau aggregates |
| Small molecule inhibitors | Preclinical | Methylene blue derivatives reduce PSP tau aggregation |
| ASO therapy | Phase 1 | MAPT-targeting ASOs reduce 4R tau expression |
| Immunotherapy combinations | Preclinical | Synergistic effects with autophagy modulators |
Advances in PSP-specific tau biomarkers: